Post by ratty on Mar 8, 2024 11:58:25 GMT
Published in January 2023, does this say what I think it says?
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
Authors: David M. Morens, Jeffery K. Taubenberger, Anthony S. Fauci
From the concluding remarks:
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
Authors: David M. Morens, Jeffery K. Taubenberger, Anthony S. Fauci
From the concluding remarks:
Durably protective vaccines against non-systemic mucosal respiratory viruses with high mortality rates have thus far eluded vaccine development efforts.
Challenges to developing next-generation respiratory vaccines are many and complex (Table 2). We must better understand why multiple sequential mucosal infections with the same circulating respiratory viruses, spread out over decades of life, fail to elicit natural protective immunity, especially with viruses that lack significant antigenic drift (e.g., RSV and parainfluenzaviruses),17,18,19,22 if we are to rationally develop vaccines that prevent them. We must think outside the box to make next-generation vaccines that elicit immune protection against viruses that survive in human populations because of their ability to remain significantly outside of the full protective reach of human innate and adaptive immunity.
Past unsuccessful attempts to elicit solid protection against mucosal respiratory viruses and to control the deadly outbreaks and pandemics they cause have been a scientific and public health failure that must be urgently addressed. We are excited and invigorated that many investigators and collaborative groups are rethinking, from the ground up, all of our past assumptions and approaches to preventing important respiratory viral diseases and working to find bold new paths forward.
Challenges to developing next-generation respiratory vaccines are many and complex (Table 2). We must better understand why multiple sequential mucosal infections with the same circulating respiratory viruses, spread out over decades of life, fail to elicit natural protective immunity, especially with viruses that lack significant antigenic drift (e.g., RSV and parainfluenzaviruses),17,18,19,22 if we are to rationally develop vaccines that prevent them. We must think outside the box to make next-generation vaccines that elicit immune protection against viruses that survive in human populations because of their ability to remain significantly outside of the full protective reach of human innate and adaptive immunity.
Past unsuccessful attempts to elicit solid protection against mucosal respiratory viruses and to control the deadly outbreaks and pandemics they cause have been a scientific and public health failure that must be urgently addressed. We are excited and invigorated that many investigators and collaborative groups are rethinking, from the ground up, all of our past assumptions and approaches to preventing important respiratory viral diseases and working to find bold new paths forward.
